Orphan disease biotech Versartis sets terms for $81 million IPO

By Renaissance Capital,

Shutterstock photo

Versartis, a biotech developing long-acting treatments for growth hormone deficiency, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $81 million by offering 4.6 million shares at a price range of $16 to $19. At the midpoint of the proposed range, it would command a fully diluted market value of $409 million. Versartis was founded in 2008 and plans to list on the NASDAQ under the symbol VSAR. Versartis initially filed confidentially on January 10, 2014. Morgan Stanley and Citi are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: VSAR

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com